iShares U.S. Pharmaceuticals ETF (IHE)
| Assets | $369.72M |
| NAV | $184.86 |
| Expense Ratio | 0.42% |
| PE Ratio | 22.72 |
| Shares Out | 2.00M |
| Dividend (ttm) | $2.71 |
| Dividend Yield | 1.47% |
| Ex-Dividend Date | Sep 24, 2021 |
| 1-Year Return | - |
| Volume | 8,154 |
| Open | 184.87 |
| Previous Close | 184.88 |
| Day's Range | 184.87 - 187.21 |
| 52-Week Low | 155.59 |
| 52-Week High | 198.62 |
| Beta | 0.88 |
| Holdings | 51 |
| Inception Date | May 1, 2006 |
About IHE
The investment seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund is non-diversified.
Top 10 Holdings
77.02% of assets| Name | Symbol | Weight |
|---|---|---|
| Johnson & Johnson | JNJ | 22.42% |
| Pfizer | PFE | 18.51% |
| Merck | MRK | 4.96% |
| Zoetis | ZTS | 4.59% |
| Royalty Pharma | RPRX | 4.58% |
| Elanco Animal Health | ELAN | 4.53% |
| Eli Lilly | LLY | 4.47% |
| Catalent | CTLT | 4.40% |
| Viatris | VTRS | 4.39% |
| Bristol-Myers Squibb | BMY | 4.17% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 24, 2021 | $0.832 | Sep 30, 2021 |
| Jun 10, 2021 | $0.72063 | Jun 16, 2021 |
| Mar 25, 2021 | $0.63484 | Mar 31, 2021 |
| Dec 14, 2020 | $0.5261 | Dec 18, 2020 |
| Sep 23, 2020 | $0.70888 | Sep 29, 2020 |
| Jun 15, 2020 | $0.31386 | Jun 19, 2020 |
News
Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan
The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.
Pharma ETFs Gain on Q2 Earnings
Many industry bigwigs reported solid results with some beating on earnings or revenues or both.
5 Sector ETFs That Survived Last Week's Turmoil
We have highlighted five sector ETFs that performed well last week and survived the broad market rout.
Pharma ETFs in Focus Post Q1 Earnings
The slew of Q1 results have led to mixed trading in pharma ETFs over the past month.
Biotech ETFs Make Gains Tuesday, Despite the J&J Vaccine Pause
Some biotech and pharmaceutical ETFs are gaining on Tuesday despite news that Johnson and Johnson's coronavirus vaccine has been halted in over two dozen states, after the Food and Drug Administration r...
ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.
Pharma ETFs in Focus Post Q4 Earnings
Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.
Q3 Earnings Fail to Impress Pharma ETFs
The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.
Best Pharmaceutical ETFs for Q1 2021
The best pharmaceutical ETFs for Q1 2021 are KURE, XPH, and IHE.
Pharma ETFs Soar on Robust Q2 Earnings
Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.
Pharma ETFs Gain on Healthy Q4 Earnings
Strong results led to solid trading in pharma ETFs over the past week.
Pharma ETFs Set to Benefit Post Strong Q3 Earnings
Robust results led to solid trading in pharma ETFs in a month.
JNJ Beats, Ups View: Healthcare ETFs to Buy
Johnson & Johnson continued its long streak of earnings beat and outpaced revenue estimates. It also raised its guidance for the full year.
Johnson & Johnson, UnitedHealth Give Healthcare ETFs a Much Needed Bolster Shot
Healthcare stocks and sector-related exchange traded funds found support from a strong start to the earnings season after UnitedHealth Group (NYSE: UNH) and Johnson & Johnson (NYSE: JNJ) provided a much...
Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?
Despite robust results, pharma ETFs have been trending downward in a month.
Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
Pharma ETFs Down Despite Solid Q1 Results
Despite such robust results, pharma ETFs have been trending downward in a month.